Atley, Stanford University and Telix Pharmaceuticals launch collaborative project to establish At-211 supply chain in California
Gothenburg, Sweden – 10 February 2026 – Atley Solutions today announces the launch of a landmark international collaboration with the Cyclotron & Radiochemistry Facility (CRF) at Stanford University and Telix Pharmaceuticals aimed to establish the first operational supply chain for astatine-211 (At-211) in California. The project has been awarded grant funding from VINNOVA under its 2025 “Deepened collaboration with USA, UK and Singapore within Health and Life Science” program.
At-211 is rapidly emerging as one of the most promising alpha-emitting radionuclides for targeted radionuclide therapy (TRT), yet access to the isotope remains extremely limited, particularly in the western United States.
California currently lacks sustainable access to At-211, an alpha-emitting radionuclide increasingly recognized for its clinical potential in targeted radionuclide therapy (TRT), particularly in metastatic cancer. The initiative brings together three leaders in radiopharmaceutical innovation to build and demonstrate the infrastructure required for future clinical translation of At-211 radiopharmaceuticals in the region.
Atley contributes its global leadership in At-211-related manufacturing technology, including its proprietary Bi-209 targets and Atley C100 platform – the world’s first commercially available system for automated At-211 purification and radiopharmaceutical synthesis. Stanford University brings a world-class radiopharmaceutical development environment, with cGMP manufacturing capacity, leading nuclear medicine researchers, and deep clinical expertise in theranostics and neuro-oncology. Telix Pharmaceuticals adds a robust radiopharmaceutical development pipeline, commercial experience across multiple geographies, and the clinical vision to advance At-211 therapies toward regulatory approval and patient use. At-211 used in the project will primarily be produced, via irradiation of Bi-209 targets, at the cyclotron located at the Crocker Nuclear Laboratory at UC Davis and may also be sourced from other cyclotrons and accelerators.
Milton Lönnroth, CEO of Atley Solutions, commented:
“Reliable access to At-211 is one of the biggest bottlenecks holding back clinical trials for At-211 drugs. This project is a major milestone for Atley and for the field, it brings our Atley C100 module into a leading U.S. academic environment and establishes the local supply needed to translate therapies faster. Ultimately, it’s about patients: enabling consistent At-211 access close to where drugs are developed and used is essential to getting powerful new alpha treatments into real clinical pathways.”
Gunilla Jacobson, PhD, Technical & Strategic Director, CRF, Stanford University, added:
“Our cGMP facility and dedicated staff are ideally suited for advancing radiopharmaceutical development, and direct access to this theranostic isotope allows us to provide new treatment opportunities to our patients at Stanford Medicine. This project solves a critical challenge in the isotope supply chain and opens the door for groundbreaking research as well as future clinical studies with At-211.”
Chad Watkins, General Manager Isotope Strategy, Telix Pharmaceuticals, stated:
“This project is highly relevant for the development of Telix’s next generation pipeline. Establishing a supply chain for At-211 in California is strategically important, supporting both near-term R&D and clinical translation of alpha therapies for the benefit of patients.”
The project will run through 2026 and includes the installation of an Atley C100 module at Stanford and the validation of the full At-211 radiopharmaceutical workflow, from target manufacturing until manufacturing of the drug product. The VINNOVA award strengthens Sweden’s position as a global enabler in emerging radiopharmaceutical technologies while laying the groundwork for long-term At-211 production capacity in the United States.
This collaboration builds on Atley’s accelerating international footprint, following recent partnerships and strategic growth achievements across Europe and the U.S.
